Yet, venetoclax resistance associated with lack of BCL2 expression has been observed in DLBCL [43] and, hence, using additive therapy employing non-apoptotic mechanisms might result in more durable responses in these cases. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.